Home > Insider Trading > Filing (0001104659-20-033491)

Filing Details

Accession Number:: 0001104659-20-033491
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-03-13 21:31:51
Reporting Period:: 2020-03-09

Accepted Time:: 2020-03-13 21:31:51
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1264587	Stemline Therapeutics Inc	STML	Pharmaceutical Preparations (2834)	450522567

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1573722	Kenneth Hoberman	C/O Stemline Therapeutics, Inc. 750 Lexington Avenue, Eleventh Floor New York NY 10022	Chief Operating Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2020-03-09	9,487	$5.08	788,468	No	4	S	Direct
Common Stock	Disposition	2020-03-10	16,704	$4.91	771,764	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Footnotes

In connection with the vesting of 17,576 shares on March 8, 2020, a total of 9,487 of such shares were sold by the Company on March 9, 2020 in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies.
Reflects the weighted average sale price. The range of prices for the shares sold on March 9, 2020 was $5.00 to $5.22. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies.
Of the listed shares, 406,152 shares are restricted stock.
In connection with the vesting of 32,867 shares on March 9, 2020, a total of 16,704 of such shares were sold by the Company on March 10, 2020 in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies.
Reflects the weighted average sale price. The range of prices for the shares sold on March 10, 2020 was $4.67 to $5.03. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies.
Of the listed shares, 373,285 shares are restricted stock.